NewsRoom Articles - Page 10 of 154 - PsychedelicNewsWire (PNW)

ThursdayJun 13, 2024 10:00 am

Study Finds That Psychedelics, Religion Weaken Link to Risky Behavior and Violence

Classic psychedelics are drugs that induce altered states of consciousness and intense auditory and visual hallucinations when ingested. Common classic psychedelics include psilocybin, LSD, DMT and mescaline. These drugs have been used for centuries by Indigenous peoples in spiritual ceremonies and healing practices. In most countries, psychedelics are illegal. Despite their status, various studies have determined that these drugs hold promise in the treatment of conditions such as anxiety, depression and post-traumatic stress disorder (PTSD). Now, new research has determined that the link between violence and risky behaviors is weaker among individuals who report lifetime psychedelic use as well as…

TuesdayJun 11, 2024 10:00 am

Psychedelic Stocks Fall as Advisory Panel Tells FDA Not to Approve MDMA

A number of companies involved in the psychedelic space saw their stocks plummet during premarket trading earlier this week after an advisory panel counseled the U.S. Food and Drug Administration (FDA) against approving the use of MDMA as a treatment for post traumatic stress disorder (PTSD). MDMA, commonly known as molly or ecstasy, is a stimulant and psychedelic drug that comes in powder or pill forms. Currently, the drug is classified under Schedule I of the Controlled Substances Act, together with drugs such as LSD, marijuana, heroin and peyote. Drugs under this classification are said to have no accepted medical…

ThursdayJun 06, 2024 10:00 am

Case Study Documents Psychedelics Aiding Patient’s Recovery from Long-COVID

Long-COVID, also referred to as post-acute sequelae of SARS-CoV-2 infection, includes various symptoms that persist even after an individual recovers from the COVID-19. These symptoms include cognitive impairment, fatigue, depression, anxiety, headaches and joint pain. Currently, effective treatment options for long-COVID are limited. However, a new case study has examined how one patient suffering from long-COVID used MDMA and psilocybin to manage her symptoms. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. It has been used by indigenous cultures for spiritual ceremonies for centuries. In the last few years, scientific research has discovered that psilocybin has therapeutic benefits…

TuesdayJun 04, 2024 10:00 am

Could Psychedelics Help Individuals Who Stutter?

A new study looking into the effect of psychedelics on individuals who stutter has determined that the drugs may have some benefits. The documented effects of classic psychedelic drugs such as LSD or psilocybin mushrooms are plenty, with researchers noting that their positive effects can be a rich study area. Eric S. Jackson, an associate professor of communicative disorders and sciences, states that investigating the possible effects of psychedelics on stuttering can be positive, particularly since the drugs have already shown potential in the management of conditions such as post-traumatic stress disorder and anxiety. Stuttering is basically intermittent disruptions in…

ThursdayMay 30, 2024 10:00 am

Study Offers Insights on Colorado’s Plans to Monitor, Regulate Psychedelics

The state of Colorado is pioneering the way once more as government leaders figure out how to establish and regulate the nascent psychedelics industry. The state was the first to legalize the recreational use of marijuana. This latest move comes after Colorado became one of the first states in the country to legalize psychedelic drugs and establish policy around their therapeutic use. Denver Health and Hospital Authority’s Joshua Black stated that while psychedelics had been used for millennia, this was the first time the substances were being approved for use by trained practitioners. Black is a senior research scientist at…

TuesdayMay 28, 2024 10:00 am

Marital Status Seems to Influence Psychedelic Outcomes, Study Shows

A recently conducted analysis has determined that people who had used psychedelics at some point in their lives experienced less psychological distress. The analysis also revealed that this link was highest in single people and significantly reduced in individuals who were married, divorced or widowed. Psychedelics are psychoactive drugs that are known to alter an individual’s mood and perception, among other things. These drugs often induce introspective experiences and powerful auditory and visual hallucinations. Classic psychedelic drugs include psilocybin, LSD, DMT and mescaline. Different studies have found positive links between psychedelic substances and health, with some highlighting the drugs’ potential…

ThursdayMay 23, 2024 11:15 am

4th Annual Psychedelic Therapeutics and Drug Development Conference Comes to Boston, MA

Researchers and leaders in academia, industry, the non-profit sector, and government organizations are invited to attend the 4th Annual Psychedelic Therapeutics and Drug Development Conference being held May 23-24, 2024, in Boston, MA. The conference focuses on discussing the hurdles as well as challenges in the research and development of psychedelics for various health conditions. Join the experts for this two-day conference that involves exploration, learning, discussion, and networking. Specific areas of discussion will include: Targets for novel drug development Toxicology studies and considerations The dosage debate and new evidence Second generation psychedelic drug design FDA regulatory guidance The speaker…

ThursdayMay 23, 2024 10:00 am

Maryland Governor Enacts Law Creating Psychedelics Task Force

Governor Wes Moore of Maryland recently signed two measures into law that will create a task force to conduct research on legal access to psychedelics such as DMT and psilocybin. This move comes almost a month after legislators forwarded the bills to the governor’s desk. The new law will establish a task force on the responsible use of natural psychedelics that shall be overseen by the state’s Cannabis Administration. The agency will oversee the equitable, broad and affordable access to psychedelics in the state. Members of this body are tasked with assessing and making recommendations on issues such as the…

TuesdayMay 21, 2024 10:00 am

Questions Arise Regarding MAPS Research on MDMA

A few months from now, the U.S. Food and Drug Administration (FDA) will be deciding whether MDMA can be prescribed as a treatment for post-traumatic stress disorder (PTSD”. MDMA, which is commonly known as ecstasy, is currently classified as a Schedule I drug under the Controlled Substances Act. The agency’s approval of the drug’s use would be a significant breakthrough, particularly for the movement that has championed for psychedelic drugs to be used in managing a range of mental health conditions. On the other hand, FDA rejection of the drug’s use for these conditions would also be a major setback…

ThursdayMay 16, 2024 10:00 am

Vermont Lawmakers Send Modified Psychedelics Therapy Bill to Governor’s Desk

Legislators in Vermont have approved a measure that would establish a task force for psychedelic therapy. The group’s primary task would be to recommend how and whether the state should regulate legal access to psychedelic drugs such as MDMA and psilocybin. The legislation is now headed to the governor’s desk. Last week, the senate approved amended language of the legislation, approving changes made in the house. In its present form, the legislation wouldn’t amend the legal status of any drugs. Rather, the working group would review the latest evidence and research on public-health risks and benefits of clinical psychedelic-assisted therapies…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000